Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
Loftus EV, Sandborn WJ..
Epidemiology of inflammatory bowel disease..
Gastroenterol Clin N Am, (2002), 31 pp. 1-20
[2]
Brulleta E, Bonfill X, Urrutia G, Ruiz Ochoa V, Cueto M, Clofent J, et al..
Estudio epidemiológico sobre la incidencia de enfermedad inflamatoria intestinal en cuatro áreas españolas..
Med Clin (Barc), (1998), 110 pp. 651-6
[3]
Krishnan A, Korzenik JR..
Inflammatory bowel disease and environmental influences..
Gastroenterol Clin N Am, (2002), 31 pp. 21-39
[4]
Tobin MV, Logan RFA..
Langman MJ, McConnell RB, Gilmore IT, et al. Cigarrette smoking and inflammatory bowel disease..
Gastroenterology, (1987), 93 pp. 316-21
[5]
Fiocchi C..
Inflammatory bowel disease: etiology and pathogenesis..
Gastroneterology, (1998), 115 pp. 182-205
[6]
Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, et al..
Transdermal nicotina for active ulcerative colitis..
N Engl J Med, (1994), 330 pp. 811-5
[7]
Andersson RE, Olaison G, Tysk C, Ekbom A..
Appendectomy is followed by increased risk of Crohn's disease..
Gastroenterology, (2003), 124 pp. 40-6
[8]
Godet PG, May GR, Sutherland LR..
Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease..
Gut, (1995), 37 pp. 668-73
[9]
Farell RJ, LaMont JT..
Microbial factors in inflammatory bowel disease..
Gastroenterol Clin N Am, (2002), 31 pp. 41-62
[10]
Peltola H, Patja A, Leinkki P, Valle M, Davidkin I, Paunio M..
No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or austism in a 14-year prospective study..
Lancet, (1998), 351 pp. 1327-58
[11]
Podolsky DK..
The current future understanding of inflammatory bowel disease..
Best Pract Res Clin Gastroenterol, (2002), 16 pp. 933-43
[12]
Duerr R..
The genetics of inflammatory bowel disease..
Gastroenterol Clin N Am, (2002), 31 pp. 63-76
[13]
Bonen DK, Cho JH..
The genetics of inflammatory bowel disease..
Gastroenterology, (2003), 124 pp. 521-36
[14]
Orholm M, Munkholm P, Langholz E, Nielsen OH, Sorensen IA, Binder V..
Familial ocurrence of inflammatory bowel disease..
N Engl J Med, (1991), 324 pp. 84-8
[15]
Hugot JP. Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L et al..
Mapping of a susceptibility locus for Crohn's disease on chromosome 16..
Nature, (1996), 379 pp. 821-3
[16]
Negoro K, Kinouchi Y, Hiwatashi N, Takashashi S, Takagi S, Satoh J et al..
Crohn's disease in associated with novel polymorphishms in the 5'flanking region of the tumor necrosis factor gene..
Gastroenterology, (1999), 117 pp. 1062-8
[17]
Elson CO..
.a ed. Nueva York: Raven.
.a ed. Nueva York: Raven, (2000), pp. 208-39
[18]
Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wirld G, et al..
in the treatment of patients with mild to moderately active Crohn's disease Gastroenterology, (2000), 119 pp. 1473-82
[19]
Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, et al..
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease..
Gastroenterology, (2000), 119 pp. 1461-72
[20]
Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, et al..
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease..
Gastroenterology, (1997), 113 pp. 118-26
[21]
Schreiber S, Nikolaus S, Hampe J..
Activation of nuclear factor κB in inflammatory bowel disease..
Gut, (1998), 42 pp. 477-84
[22]
Segain JP, Raingeard de la Bletiere D, Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, et al..
Rho Kinase blockade prevents inflammation via nuclear factor κB inhibition: Evidence in Crohn's disease and experimental colitis..
Gastroenterology, (2003), 124 pp. 1180-7
[23]
Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, et al..
Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis..
Gastroenterology, (1999), 116 pp. 557-65
[24]
Roman LI, Manzano L, De La Hera A, Abreu L, Rossi I, Álvarez-Mon M..
Expanded CD4+CD45RO+ phenotype and defective proliferative response in T lymphocytes from patients with Crohn's disease..
Gastroenterology, (1996), 110 pp. 1008-19
[25]
García de Tena J, Manzano M, Leal JC, Prieto A, San Antonio E, Álvarez-Mon M..
Expansion of peripheral blood memory CD+CD28null T cells in patients with active Crohn's disease..
Eur J Intern Med, (2001), 12 pp. 272
[26]
Increased expression of tumor necrosis factor (TNF) in peripheral blood memory CD4+ T cells of patients with Crohn's disease. Gastroenterology 2001;120 (suppl. 1):A-317.
[27]
Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al..
Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease..
N Engl J Med, (2003), 348 pp. 24-32
[28]
Peeters M, Joossens S, Bermeire S, Vlietinck R, Bossuyt X, Rutgeerts P..
Diagnostic value of anti-Saccharomyces cerevisiae and antineytrophil cytoplasmic aytonatibodies in inflammatory bowel disease..
Am J Gastroenterol, (2001), 96 pp. 730-4
[29]
Manzano L, Álvarez-Mon M, Abreu L, Antonio Vargas J, de la Morena E, Corugedo F, et al..
Functional impairment of natural killer cells in active ulcerative colitis. Reversion of the defective natural killer activity by interleukin 2..
Gut, (1992), 33 pp. 246-51
